Latest On NuCana plc (NCNA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-18 02:26 EST | News | NuCana GAAP EPS of -£0.15 | N/A |  |
| 2023-05-12 19:29 EST | News | NuCana gets Nasdaq notice for listing noncompliance | N/A | |
| 2023-04-05 02:16 EST | News | NuCana GAAP EPS of -£0.29 | N/A | |
| 2023-03-27 10:32 EST | News | NuCana falls 36% after setback for patent dispute in EU for Gilead’s antiviral | N/A | |
| 2023-01-08 11:10 EST | News | NuCana: Pipeline And Major Gilead Litigation Progressing Nicely | N/A | |
| 2022-11-16 23:50 EST | News | NuCana GAAP EPS of -£0.09 | N/A | |
| 2022-09-23 04:53 EST | News | NuCana: An Intriguing 'Sum Of The Parts' Story | N/A | |
| 2022-08-18 06:00 EST | News | NuCana GAAP EPS of -£0.07 | N/A | |
| 2022-07-27 14:42 EST | News | NuCana regains Nasdaq compliance | N/A | |
| 2022-07-13 11:03 EST | News | NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead | N/A | |
| 2022-06-04 13:13 EST | News | NuCana gets Nasdaq non-compliance notice on minimum bid price | N/A | |
| 2022-06-02 20:32 EST | News | NuCana GAAP EPS of -£0.16 | N/A | |
| 2022-04-28 08:25 EST | News | NuCana GAAP EPS of -£0.26 | N/A | |
| 2022-03-03 23:55 EST | News | NuCana falls on decision to halt late-stage study for biliary tract cancer | N/A | |
| 2021-12-08 00:44 EST | News | NuCana: Preparing For A Critical 2022 | N/A | |
| 2021-09-30 07:27 EST | News | NuCana shares surge 21% on FDA Fast Track status for Acelarin cancer treatment | N/A | |
| 2021-09-22 18:53 EST | News | NuCana completes enrollment in late-stage Acelarin biliary tract cancer study | N/A | |
| 2021-09-11 10:12 EST | News | NuCana: The Market Continues To Overlook Its ProTide Platform Technology | N/A | |
| 2021-08-19 21:13 EST | News | NuCana reports Q2 results | N/A | |
| 2021-08-10 18:45 EST | News | NuCana appoints Jeffrey Bloss as new chief medical officer | N/A | |
| 2021-07-22 16:59 EST | News | NuCana: Starting A Speculative Position At An Astonishing Risk-Reward | N/A | |
| 2021-03-12 17:55 EST | Analyst Rating | The Analyst Target Price has decreased from $1163.58 to $1160.57. | Neutral | |
| 2021-03-08 02:08 EST | Analyst Rating | The Analyst Target Price has decreased from $1170.59 to $1163.58. | Neutral | |
| 2021-03-06 14:08 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-05 18:00 EST | Analyst Rating | The Analyst Target Price has increased from $1155.19 to $1170.59. | Buy | |
| 2021-03-05 13:08 EST | News | NuCana reports Q4 results | N/A | |
| 2021-03-05 02:46 EST | Earnings Estimate | An EPS average of -$17.40 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-05 02:46 EST | Earnings Estimate | An EPS average of -$103.93 is estimated for the 2022 year. | Sell | |
| 2021-03-03 20:41 EST | News | Circling Back On NuCana Stock | N/A | |
| 2021-02-26 17:51 EST | Analyst Rating | The Analyst Target Price has decreased from $1179.05 to $1155.19. | Neutral | |
| 2021-02-19 17:39 EST | Analyst Rating | The Analyst Target Price has decreased from $1181.18 to $1179.05. | Neutral | |
| 2021-02-12 13:52 EST | Analyst Rating | The Analyst Target Price has decreased from $1197.1 to $1181.18. | Neutral | |
| 2021-02-05 13:54 EST | Analyst Rating | The Analyst Target Price has increased from $1193.43 to $1197.1. | Buy | |
| 2021-01-29 14:14 EST | Analyst Rating | The Analyst Target Price has decreased from $1196.32 to $1193.43. | Neutral | |
| 2021-01-22 14:28 EST | Analyst Rating | The Analyst Target Price has decreased from $1197.72 to $1196.32. | Neutral | |
| 2021-01-15 20:40 EST | News | NuCana's NUC-3373 demonstrates encouraging data in metastatic colorectal cancer | N/A | |
| 2021-01-15 14:22 EST | Analyst Rating | The Analyst Target Price has decreased from $1200.37 to $1197.72. | Neutral | |
| 2021-01-08 14:25 EST | Analyst Rating | The Analyst Target Price has increased from $1199.05 to $1200.37. | Buy | |
| 2021-01-01 14:32 EST | Analyst Rating | The Analyst Target Price has decreased from $1210.59 to $1199.05. | Neutral | |
| 2020-12-25 18:39 EST | Analyst Rating | The Analyst Target Price has increased from $1209.25 to $1210.59. | Buy | |
| 2020-12-18 15:41 EST | Analyst Rating | The Analyst Target Price has decreased from $1219.27 to $1209.25. | Neutral | |
| 2020-12-11 14:38 EST | Analyst Rating | The Analyst Target Price has decreased from $1222.27 to $1219.27. | Neutral | |
| 2020-12-04 19:14 EST | Analyst Rating | The Analyst Target Price has increased from $1217.54 to $1222.27. | Buy | |
| 2020-12-04 06:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-03 06:14 EST | Analyst Rating | The Analyst Target Price has decreased from $1251.15 to $1217.54. | Neutral | |
| 2020-12-02 15:03 EST | Analyst Rating | The Analyst Target Price has decreased from $1314.41 to $1251.15. | Neutral | |
| 2020-12-01 15:17 EST | Analyst Rating | The Analyst Target Price has decreased from $1320.18 to $1314.41. | Neutral | |
| 2020-11-27 15:31 EST | Analyst Rating | The Analyst Target Price has decreased from $1326.02 to $1320.18. | Neutral | |
| 2020-11-27 00:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-25 06:58 EST | Analyst Rating | The Analyst Target Price has decreased from $1356.55 to $1326.02. | Neutral | |
About NuCana plc (NCNA):
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
General
- Name NuCana plc
- Symbol NCNA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 27
- Fiscal Year EndDecember
- IPO Date2017-09-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.nucana.com
View More
Valuation
- Price/Book (Most Recent Quarter) 2.07
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$71.68
- Next Year EPS Estimate -$90.90
- Next Quarter EPS Estimate -$16.20
- Return on Assets -23%
- Return on Equity -38%
- Earnings Per Share -$0.63
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 271.23 million
- Analyst Target Price $1160.57
- Book Value Per Share $3.50
View More
Share Statistics
- Shares Outstanding 51.17 million
- Shares Float 32.15 million
- % Held by Insiders 42%
- % Held by Institutions 53.71%
- Shares Short 76762
- Shares Short Prior Month 42974
- Short Ratio 0.23
View More
Technicals
- Beta 0.84
- 52 Week High $7.77
- 52 Week Low $4.25
- 50 Day Moving Average 5.63
- 200 Day Moving Average 5.19
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
NuCana plc (NCNA) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
NuCana plc (NCNA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $N/A | -$0.34 | -$0.23 | -46.21% |
| 2020-09-30 | 2020-11-19 | $N/A | -$0.32 | -$0.24 | -30.44% |
| 2020-06-30 | 2020-08-19 | $N/A | -$0.25 | -$0.22 | -12.08% |
| 2020-03-31 | 2020-05-19 | $N/A | -$0.15 | -$0.23 | 36.07% |
| 2019-12-31 | 2020-03-10 | $N/A | -$0.31 | -$0.21 | -48.71% |
| 2019-09-30 | 2019-11-13 | $N/A | -$0.15 | -$0.28 | 45.82% |
| 2019-06-30 | 2019-08-21 | $N/A | -$0.17 | -$0.24 | 28.69% |
| 2019-03-31 | 2019-05-14 | $N/A | -$0.22 | -$0.26 | 16% |
| 2018-12-31 | 2019-03-07 | $N/A | -$0.14 | -$0.24 | 40.69% |
| 2018-09-30 | 2018-11-27 | $N/A | -$0.10 | -$0.28 | 63.61% |
| 2018-06-30 | 2018-08-28 | $N/A | -$0.05 | -$0.26 | 80.37% |
| 2018-03-31 | 2018-05-23 | $N/A | -$0.27 | -$0.22 | -22.24% |
NuCana plc (NCNA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 7.98 million | N/A | 5.86 million | 5.94 million | 5.18 million |
| Income Before Tax | -13.96 million | N/A | -7.34 million | -5.28 million | -8.93 million |
| Selling General Administrative | 1.91 million | N/A | 1.63 million | 1.61 million | 1.72 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -9.66 million | N/A | -7.27 million | -7.33 million | -6.7 million |
| Operating Income | -9.89 million | N/A | -7.49 million | -7.55 million | -6.9 million |
| Income Tax Expense | -1.7 million | -1.2 million | N/A | N/A | -15.55 million |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | -4.08 million | N/A | 84000 | 2.13 million | -2.21 million |
| Net Income From Continuing Operations | -12.26 million | N/A | -6.06 million | -3.97 million | -7.71 million |
| Net Income Applicable to Common Shares | -12.26 million | -8.39 million | N/A | N/A | -98.33 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -318000 | -221000 | -43000 | 31000 |
| Change to Liabilities | 2.26 million | N/A | N/A | 3.28 million | -870643.68 |
| Total Cash Flow from Investing Activities | -590000 | N/A | N/A | -548530.06 | 198455.53 |
| Net Borrowings | -75000 | N/A | N/A | -650582.14 | -326491.43 |
| Total Cash Flow from Financial Activities | N/A | 1.87 million | -73000 | -18000 | -20000 |
| Change to Operating Activities | -897000 | N/A | N/A | 19.47 million | -20.04 million |
| Change in Cash | N/A | 112000 | -6.5 million | -3.92 million | -8.33 million |
| Total Cash from Operating Activities | -4.99 million | -1.44 million | -6.21 million | -49.27 million | -53.37 million |
| Depreciation | N/A | 223000 | 217000 | 196000 | 186000 |
| Other Cash Flow from Investing Activities | 21000 | N/A | N/A | 2.56 million | 1.88 million |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -4.39 million | N/A | N/A | 318912.83 | 160044.78 |
| Change to Net Income | 1.81 million | N/A | N/A | 23.82 million | -8.83 million |
| Capital Expenditures | N/A | 410000 | 408000 | 244000 | 262000 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 8.56 million | N/A | 6.97 million | 6.56 million | 6.75 million |
| Total Stockholder Equity | 99.23 million | N/A | 57.13 million | 60.43 million | 63.52 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | 107.79 million | N/A | 64.1 million | 67 million | 70.27 million |
| Common Stock | 142.94 million | 142.94 million | N/A | N/A | 1.03 billion |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -110.59 million | -98.4 million | -90.01 million | -84.02 million | -80.06 million |
| Other Liabilities | 46000 | 46000 | N/A | N/A | 331669.35 |
| Other Assets | 44000 | 34000 | N/A | N/A | 586799.62 |
| Cash | 87.36 million | N/A | 47.8 million | 47.6 million | 51.96 million |
| Total Current Liabilities | 8.15 million | 9.12 million | 6.52 million | 6.05 million | 6.18 million |
| Other Stockholder Equity | 66.89 million | 65.74 million | N/A | N/A | 800.31 million |
| Property, Plant & Equipment | 1.19 million | 1.28 million | N/A | N/A | 14.15 million |
| Total Current Assets | 101.81 million | 113.88 million | 58.61 million | 61.69 million | 65.15 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 94.48 million | 105.59 million | N/A | N/A | 759.8 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.26 million | 4.19 million | 1.93 million | 2.46 million | 2.41 million |
NuCana plc (NCNA) Chart:
NuCana plc (NCNA) News:
Below you will find a list of latest news for NuCana plc (NCNA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
NuCana plc (NCNA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest NCNA Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 3:50 PM EST | 3 | $0.67 |
| Jun 13, 2022 5:46 PM EST | 6 | $0.68 |
| Jun 13, 2022 6:42 PM EST | 7 | $0.67 |
NuCana plc (NCNA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520180926/0001193125-20-180926-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000085874419000017/0000858744-19-000017-index.htm |
| 2020-09-28 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1709626/000090571820000990/0000905718-20-000990-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000110465919008348/0001104659-19-008348-index.htm |
| 2019-03-22 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000110465919016794/0001104659-19-016794-index.htm |
| 2019-05-24 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000110465919031737/0001104659-19-031737-index.htm |
| 2020-01-16 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000110465920004809/0001104659-20-004809-index.htm |
| 2020-02-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1709626/000110465920016796/0001104659-20-016796-index.htm |
| 2020-10-05 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1709626/000110465920111873/0001104659-20-111873-index.htm |
| 2020-10-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1709626/000110465920118926/0001104659-20-118926-index.htm |
| 2019-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1709626/000114420419007797/0001144204-19-007797-index.htm |
| 2019-01-23 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519014872/0001193125-19-014872-index.htm |
| 2019-01-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519016529/0001193125-19-016529-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000119312519040776/0001193125-19-040776-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000119312519040796/0001193125-19-040796-index.htm |
| 2019-03-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519067208/0001193125-19-067208-index.htm |
| 2019-05-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519146542/0001193125-19-146542-index.htm |
| 2019-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519159572/0001193125-19-159572-index.htm |
| 2019-06-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519171768/0001193125-19-171768-index.htm |
| 2019-06-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519184310/0001193125-19-184310-index.htm |
| 2019-07-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519195165/0001193125-19-195165-index.htm |
| 2019-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519224864/0001193125-19-224864-index.htm |
| 2019-08-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519226043/0001193125-19-226043-index.htm |
| 2019-10-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519274091/0001193125-19-274091-index.htm |
| 2019-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519276871/0001193125-19-276871-index.htm |
| 2019-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519291129/0001193125-19-291129-index.htm |
| 2019-12-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312519324923/0001193125-19-324923-index.htm |
| 2020-01-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520014746/0001193125-20-014746-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000119312520038130/0001193125-20-038130-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000119312520038132/0001193125-20-038132-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000119312520038152/0001193125-20-038152-index.htm |
| 2020-03-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520060891/0001193125-20-060891-index.htm |
| 2020-03-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520068755/0001193125-20-068755-index.htm |
| 2020-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520096023/0001193125-20-096023-index.htm |
| 2020-05-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520133802/0001193125-20-133802-index.htm |
| 2020-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520143311/0001193125-20-143311-index.htm |
| 2020-05-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520144512/0001193125-20-144512-index.htm |
| 2020-05-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520146162/0001193125-20-146162-index.htm |
| 2020-06-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520158467/0001193125-20-158467-index.htm |
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520180926/0001193125-20-180926-index.htm |
| 2020-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520224701/0001193125-20-224701-index.htm |
| 2020-08-19 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1709626/000119312520224739/0001193125-20-224739-index.htm |
| 2020-09-16 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520247188/0001193125-20-247188-index.htm |
| 2020-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520247193/0001193125-20-247193-index.htm |
| 2020-09-17 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520248116/0001193125-20-248116-index.htm |
| 2020-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520249116/0001193125-20-249116-index.htm |
| 2020-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520250181/0001193125-20-250181-index.htm |
| 2020-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1709626/000119312520268529/0001193125-20-268529-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000121390019002539/0001213900-19-002539-index.htm |
| 2019-04-15 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000121390019006367/0001213900-19-006367-index.htm |
| 2019-09-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000121390019017505/0001213900-19-017505-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000121465919001006/0001214659-19-001006-index.htm |
| 2020-06-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000121465920005533/0001214659-20-005533-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000142284819000087/0001422848-19-000087-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000142284820000071/0001422848-20-000071-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000156223020000041/0001562230-20-000041-index.htm |
| 2020-03-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709626/000156223020000061/0001562230-20-000061-index.htm |
| 2019-03-07 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709626/000156459019006811/0001564590-19-006811-index.htm |
| 2020-03-10 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709626/000156459020009788/0001564590-20-009788-index.htm |